{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T13:20:22Z","timestamp":1758892822352,"version":"3.41.2"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T00:00:00Z","timestamp":1620777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We describe the case of a 54-year-old male receiving intermittent hemodialysis (iHD) who was found to have Pseudomonas aeruginosa bacteremia secondary to osteomyelitis of the calcaneus bone. The patient was clinically cured without recurrence using a ceftolozane\/tazobactam (CTZ) dosing strategy of 100\/50 mg every 8 hours (standard dosing) and 1000\/500 mg thrice weekly following iHD. Utilizing a susceptibility breakpoint of \u22644 \u00b5g\/mL for P. aeruginosa, the T &amp;gt; MIC for standard dosing and the 1000\/500-mg thrice-weekly following iHD regimen were calculated to be 92.7% and 94.1%, respectively. Ceftolozane total body clearance for the standard q 8 h dosing and the 1000\/500-mg thrice-weekly following iHD regimen were calculated to be 0.196 L\/h and 0.199 L\/h, respectively. To our knowledge, this is the first report to illustrate the administration of CTZ at a dose of 1000\/500 mg thrice weekly following iHD.<\/jats:p>","DOI":"10.1093\/ofid\/ofab238","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T11:17:40Z","timestamp":1620818260000},"source":"Crossref","is-referenced-by-count":4,"title":["A Novel Dosing Strategy of Ceftolozane\/Tazobactam in a Patient Receiving Intermittent Hemodialysis"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8873-1451","authenticated-orcid":false,"given":"Sunish","family":"Shah","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services, Yale New Haven Health System, New Haven, Connecticut, USA"},{"name":"Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P","family":"Nicolau","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dayna","family":"McManus","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Yale New Haven Health System, New Haven, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey E","family":"Topal","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Yale New Haven Health System, New Haven, Connecticut, USA"},{"name":"Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,5,12]]},"reference":[{"key":"2021070723392433500_CIT0001","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0272-6386(12)80091-6","article-title":"Mortality in dialysis patients: analysis of the causes of death","volume":"18","author":"Mailloux","year":"1991","journal-title":"Am J Kidney Dis"},{"key":"2021070723392433500_CIT0002","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1186\/s12879-016-1701-1","article-title":"Risk factors to predict drug-resistant pathogens in hemodialysis-associated pneumonia","volume":"16","author":"Wang","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2021070723392433500_CIT0003","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.cmi.2020.11.032","article-title":"Does dose reduction of renally cleared antibiotics in patients with impaired renal function lead to adequate drug exposure? A systematic review","volume":"27","author":"de Vroom","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2021070723392433500_CIT0004","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijantimicag.2018.11.001","article-title":"Ceftolozane\/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience","volume":"53","author":"Bassetti","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2021070723392433500_CIT0005","first-page":"e02291","article-title":"Real-world experience with ceftolozane-tazobactam for multidrug-resistant gram-negative bacterial infections. Antimicrob Agents Chemother","author":"Jorgensen","year":"2020"},{"volume-title":"Zerbaxa (Ceftolozane\/Tazobactam). Package insert","year":"2015","key":"2021070723392433500_CIT0006"},{"key":"2021070723392433500_CIT0007","doi-asserted-by":"crossref","first-page":"XXX\u2013XX","DOI":"10.1093\/ofid\/ofy280","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: a multicenter study","volume":"5","author":"Gallagher","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2021070723392433500_CIT0008","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/MNH.0000000000000066","article-title":"The changing landscape of home dialysis in the United States","volume":"23","author":"Rivara","year":"2014","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2021070723392433500_CIT0009","first-page":"142","article-title":"Effect of hemodialysis on ceftazidime pharmacokinetics","volume":"24","author":"Nikolaidis","year":"1985","journal-title":"Clin Nephrol"},{"key":"2021070723392433500_CIT0010","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0272-6386(01)80126-8","article-title":"Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers","volume":"37","author":"Sowinski","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"2021070723392433500_CIT0011","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/chromsci\/bmw047","article-title":"Development of an HPLC method for the determination of ceftolozane\/tazobactam in biological and aqueous matrixes","volume":"54","author":"Sutherland","year":"2016","journal-title":"J Chromatogr Sci"},{"year":"2021","author":"InsightRX, Inc","key":"2021070723392433500_CIT0012"},{"key":"2021070723392433500_CIT0013","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1128\/AAC.02151-13","article-title":"Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam","volume":"58","author":"Wooley","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070723392433500_CIT0014","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1128\/AAC.01590-12","article-title":"In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum \u03b2-lactamases, in the thighs of neutropenic mice","volume":"57","author":"Craig","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070723392433500_CIT0015","doi-asserted-by":"crossref","first-page":"6311","DOI":"10.1128\/AAC.03572-14","article-title":"Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic\/pharmacodynamic target","volume":"58","author":"Lepak","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070723392433500_CIT0016","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/jcph.566","article-title":"Ceftolozane\/tazobactam pharmacokinetic\/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia","volume":"56","author":"Xiao","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"2021070723392433500_CIT0017","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1093\/ofid\/ofy343","article-title":"Geographic and temporal patterns of antimicrobial resistance in Pseudomonas aeruginosa over 20 years from the sentry antimicrobial surveillance program, 1997\u20132016","volume":"6","author":"Shortridge","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2021070723392433500_CIT0018","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/j.ajkd.2017.08.023","article-title":"Insights from the 2016 peer kidney care initiative report: still a ways to go to improve care for dialysis patients","volume":"71","author":"Wetmore","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"2021070723392433500_CIT0019","doi-asserted-by":"crossref","first-page":"XXX\u2013XX","DOI":"10.1093\/ofid\/ofaa309","article-title":"Out of sight but not out of mind: caring for patients receiving OPAT during the SARS-CoV-2 pandemic","volume":"7","author":"Rivera","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2021070723392433500_CIT0020","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1128\/AAC.01752-10","article-title":"In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms","volume":"56","author":"Bulik","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070723392433500_CIT0021","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/jac\/dkaa049","article-title":"Lung penetration, bronchopulmonary pharmacokinetic\/pharmacodynamic profile and safety of 3 g of ceftolozane\/tazobactam administered to ventilated, critically ill patients with pneumonia","volume":"75","author":"Caro","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2021070723392433500_CIT0022","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.2146\/ajhp170056","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa pneumonia in a patient receiving intermittent hemodialysis","volume":"75","author":"Alessa","year":"2018","journal-title":"Am J Health Syst Pharm"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofab238\/37926034\/ofab238.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/8\/6\/ofab238\/38654175\/ofab238.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/8\/6\/ofab238\/38654175\/ofab238.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T02:17:16Z","timestamp":1625710636000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofab238\/6274492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,12]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofab238","relation":{},"ISSN":["2328-8957"],"issn-type":[{"type":"electronic","value":"2328-8957"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2021,5,12]]},"article-number":"ofab238"}}